Economic Evaluation of Boceprevir for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus Infection in Hungary

Raymond Odhiambo; Jagpreet Chhatwal; Shannon Allen Ferrante; Antoine El Khoury; Elamin Elbasha

doi:10.36469/9854

Loading [Contrib]/a11y/accessibility-menu.js

This website uses cookies

We use cookies to enhance your experience and support COUNTER Metrics for transparent reporting of readership statistics. Cookie data is not sold to third parties or used for marketing purposes.

JHEOR

Articles
For Authors
Editorial Board
About
Issues
Blog
Journal Policies
For Reviewers

search
X (formerly Twitter) (opens in a new tab)
Bluesky (opens in a new tab)
LinkedIn (opens in a new tab)
RSS feed (opens a modal with a link to feed)

RSS Feed

Enter the URL below into your favorite RSS reader.

http://localhost:38561/feed

ISSN 2327-2236

Infectious Diseases

Vol. 1, Issue 1, 2013

June 05, 2013 EDT

Economic Evaluation of Boceprevir for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus Infection in Hungary

Raymond Odhiambo, Jagpreet Chhatwal, Shannon Allen Ferrante, Antoine El Khoury, Elamin Elbasha,

ribavirinpeginterferonmarkov modelcost-effectivenessboceprevirchronic hepatitis c

ccby-4.0

• https://doi.org/10.36469/9854

JHEOR

Odhiambo R, Chhatwal J, Ferrante SA, El Khoury A, Elbasha E. Economic Evaluation of Boceprevir for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus Infection in Hungary. JHEOR. 2013;1(1):62-82. doi:10.36469/9854

View more stats